Tekmira to Present at 2013 Wedbush Life Sciences Conference
August 07, 2013 16:31 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Conference Call and Webcast Advisory: Corporate Update and Second Quarter Financial Results
August 06, 2013 16:05 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
July 18, 2013 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, July 18, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Tekmira's LNP Technology Enables Alnylam's Positive Phase II ALN-TTR02 Data
July 01, 2013 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, July 1, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Announces Election of Directors
May 17, 2013 18:15 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 17, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Presents LNP Technology Innovations at Scientific Symposium
May 15, 2013 16:15 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 15, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Provides Corporate Update and Announces First Quarter 2013 Results
May 14, 2013 16:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 14, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter Financial Results
May 09, 2013 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 9, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it...
Tekmira Provides Update on U.S. Government Sponsored TKM-Ebola Program
May 08, 2013 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 8, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira's Collaborators at the National Cancer Institute Present Preclinical Data at the Annual Meeting of the American Association for Cancer Research (AACR)
April 10, 2013 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 10, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...